Prostate Cancer
Comparison of PSMA immunohistochemistry scoring systems to parametric [18F]PSMA-1007 PET/MRI in primary prostate cancer.
September 16, 2024
Effectiveness of ChatGPT 4.0 in Telemedicine-Based Management of Metastatic Prostate Carcinoma.
September 16, 2024
Targeted Prostate Biopsy: How, When, and Why? A Systematic Review.
September 16, 2024
Targeting adenocarcinoma and enzalutamide‑resistant prostate cancer using the novel anti‑androgen inhibitor ADA‑308.
September 14, 2024
Androgen receptor monomers and dimers regulate opposing biological processes in prostate cancer cells.
September 14, 2024
Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer.
September 14, 2024
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
September 13, 2024
Quantification of Gleason Pattern 4 Metrics Identifies Pathologic Progression in Patients With Grade Group 2 Prostate Cancer on Active Surveillance.
September 13, 2024
Liquid Biopsy in Progressing Prostate Cancer Patients Starting Docetaxel with or Without Enzalutamide: A Biomarker Study of the PRESIDE Phase 3b Trial.
September 13, 2024
Systematic review and recommendations for re-irradiation for intraprostatic radiorecurrent prostate cancer after definitive radiation therapy.
September 13, 2024
Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.
September 13, 2024
YAP1 Inhibition Induces Phenotype Switching of Cancer-Associated Fibroblasts to Tumor Suppressive in Prostate Cancer.
September 13, 2024
PIONEER big data platform for prostate cancer: lessons for advancing future real-world evidence research.
September 13, 2024